The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 801–900 of 933
Parhofer, K. G. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0233-7 · Cited by 1
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
Rabast, U. (2018) · Springer eBooks · doi:10.1007/978-3-662-56512-4_2 · Cited by 1
N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease
Barringer, T. A., Harris, W. S., Fleming, J. A., & Kris‐Etherton, P. M. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_21 · Cited by 1
Controversial Issues in the Treatment of Dyslipidemias in Patients with Diabetes Mellitus
Parhofer, K. G. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002574 · Cited by 1
Bentz, A. J., Netland, P. J., Newman, W. P., Froemke, L. L., Miller, R. R., & Schiele, R. L. (2018) · Europe PMC (PubMed Central) · Cited by 1
Association of polyunsaturated fatty acids treatment with coronary mortality. A meta-analysis
Плавинский, С. Л., Barinova, A. N., & Danishevski, K. D. (2019) · Kardiologiia · doi:10.18087/cardio.n680 · Cited by 1
Translating Evidence From Clinical Trials of omega-3 Fatty Acids to Clinical Practice
Nelson, A. J., & Nicholls, S. J. (2020) · Future Cardiology · doi:10.2217/fca-2019-0031 · Cited by 1
Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease
Mahajan, K., & Chandra, K. S. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620943020 · Cited by 1
Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids)
Evans, M. C., & Miller, M. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_15 · Cited by 1
Chan, J., Svensson, M. H. S., Jenssen, T. G., Schmidt, E. B., & Eide, I. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244089 · Cited by 1
Effects of omega-3 fatty acids, vitamins, and chelation therapy in patients with heart diseases
Joo, S.-J. (2021) · Journal of Medicine and Life Science · doi:10.22730/jmls.2021.18.1.1 · Cited by 1
ÁCIDOS GRAXOS E O SISTEMA CARDIOVASCULAR
Nasciutti, P. R., Costa, A. P. A., Júnior, M. B. D. S., Melo, N. D. F. M., & Carvalho, R. D. O. A. (2015) · Enciclopédia Biosfera · doi:10.18677/enciclopedia_biosfera_2015_066 · Cited by 1
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.11.009 · Cited by 1
Are U‐shaped relationships between risk factors and outcomes artifactual?
Shah, R., Thabane, L., & Gerstein, H. C. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13335 · Cited by 1
Permanenter Anstieg unserer Lebenserwartung
Rabast, U. (2022) · Springer eBooks · doi:10.1007/978-3-662-65230-5_1 · Cited by 1
Benefits of omega-3 polyunsaturated fatty acids to patients with oral and metabolic diseases
Da-Ming, L., & Chieh, C. (2023) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000061 · Cited by 1
Abdelfattah, O., Sayed, A., Al-Refaei, A., Abdeldayem, J., Moustafa, K., Elias, N., & Saleh, Y. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070008 · Cited by 1
Clifton, P. M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_21 · Cited by 1
Mohammedi, K., Pigeyre, M., Bosch, J., Yusuf, S., & Gerstein, H. C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02383-z · Cited by 1
Defining the Role of Icosapent Ethyl in Clinical Practice
Chatterjee, S., Hajra, A., Bandyopadhyay, D., Ghosh, R. K., & DEEDWANIA, P. C. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00402-4 · Cited by 1
Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
Arnold, S. V., GOSCH, K. L., Wong, N. D., Hejjaji, V., Goyal, A., Leiter, L. A., & Kosiborod, M. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.126 · Cited by 1
Omega-3-fettsyrer - både mat og medisin
Retterstøl, K. (2012) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.1006 · Cited by 1
Tatsuno, I. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed063 · Cited by 1
Access to clinical trial data—Commentary
Devereaux, P. J. (2019) · Clinical Trials · doi:10.1177/1740774519865528 · Cited by 1
Which Is Better to Prevent Cardiovascular Events, Only EPA or the Combination of EPA and DHA?
Yanai, H. (2016) · Journal of Endocrinology and Metabolism · doi:10.14740/jem359w · Cited by 1
Proteomics: a tool to investigate of composition and function of HDL in hyperlipidemia
da Silva, A. R. M. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-26082022-123137 · Cited by 1
Viljoen, A., Handhle, A., & Wierzbicki, A. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch48 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Fettstoffwechsel und Hypertonie bei Diabetes
Drexel, H., Jacob, S., Parhofer, K. G., Säly, C., Schatz, H., & Vonbank, A. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_7
Chapitre 24 – Thérapeutiques antidiabétiques
Wémeau, J.-L. (2014) · doi:10.1016/b978-2-294-71584-6.00024-6
Bogl, L. H. (2014) · Työväentutkimus Vuosikirja
Gohlke, H., Albus, C., Bönner, G., Darius, H., Eckert, S., Gohlke-Bärwolf, C., Gysan, D. B., Hahmann, H., Halle, M., Hambrecht, R., et al. (2013) · Der Kardiologe · doi:10.1007/s12181-012-0468-x
Kardiovaskuläres Risiko und medikamentöse Lipidtherapie
Stulnig, T. M. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0891-4
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Little, P. J., Chait, A., Januszewski, A. S., Bobik, A., O'Neal, D. N., & Jenkins, A. J. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_23
Adipositas und Omega-3-Fettsäuren
Blüher, M., Ceglarek, U., Thiery, J., Hamm, M., & Richter, V. (2014) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0037-1618832
N-3 fatty acids did not reduce major cardiovascular events in patients with dysglycaemia
Kromhout, D. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2012-101012
Rajagopalan, S. (2015) · Journal of Indian College of Cardiology · doi:10.1016/j.jicc.2015.03.006
Does glycemic control reduce cardiovascular event rates?
Lim, G. B. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.96
Physician decision criteria regarding omega-3 dietary supplements
Lesser, W. P. (2014) · ScholarWorks (Walden University)
Neue Entwicklungen in der Lipidtherapie
Parhofer, K. G. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0892-3
Optimal use of lipid-altering therapy: guidelines versus evidence
Hilleman, D. E. (2013) · Clinical Lipidology · doi:10.2217/clp.13.18
Combination pharmacotherapy in lipid management
Lee, S. (2015) · Journal of Korean Medical Association · doi:10.5124/jkma.2015.58.8.745
Hyperlipidemia: Where Is the Evidence for Combination Therapy?
Tannock, L. R. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch26
Hypertriglyceridemia: Should We Treat?
Brinton, E. A. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch27
Lee, Y. R. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.3.205
Aktuelle Lipidtherapie bei Diabetes mellitus
Lebherz, C. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0068-7
Gebauer, S., & Pfeiffer, A. F. H. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1192-2
Poggiogalle, E., Polidoro, G., Emerenziani, G. P., Marocco, C., Lazzaro, L. D., Lubrano, C., Migliaccio, S., Lenzi, A., & Donini, L. M. (2014) · Nutrition Clinique et Métabolisme · doi:10.1016/s0985-0562(14)70790-3
Change of heart: Mixed evidence on omega-3 FAs
Hume, A. L. (2013) · Pharmacy Today · doi:10.1016/s1042-0991(15)31334-7
Marine n-3 polyunsaturated fatty acids in renal transplantation
Eide, I. A. (2016) · NORA - Norwegian Open Research Archives
Watada, H. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.902
Zufallsbefund Hypertriglyzeridämie
Parhofer, K. G. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2917-5
Omega-3-Fettsäuren wirkungslos
Mai, K. (2012) · Info Diabetologie · doi:10.1007/s15034-012-0215-1
Diet Modification After Acute Coronary Events
de Keizer, L., & Chow, C. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418680-4.00031-2
What's new in nutrition for adults with diabetes?
Nwankwo, R. B., & Funnell, M. M. (2016) · Nursing Management · doi:10.1097/01.numa.0000491124.22612.0e
Диабетическая кардиальная автономная нейропатия: каковы перспективы в лечении?
Сергієнко, В. О., & Serhiyenko, O. (2016) · HYPERTENSION · doi:10.22141/2224-1485.1.45.2016.74137
Linoleic acid and leukocyte inflammatory markers in periparturient dairy cows
Raphael, W. (2014) · Michigan State University Libraries · doi:10.25335/m5ch79
¿Cuáles son las novedades en nutrición para adultos con diabetes?
Nwankwo, R. B., & Funnell, M. M. (2016) · Nursing (Ed española) · doi:10.1016/j.nursi.2016.11.008
Consenso Gallego Multidisciplinar sobre el Uso de Hipolipemiantes
López, B., Díaz, A., Rodríguez, J. M. V., Piñeiro, P. B., Isorna, C. C., Freijomil, A. P., Díaz, J. L. D., Pérez Freijomil, A., Aldana, D. R., & Castro Iglesias, A. (2016) · Galicia Clínica · doi:10.22546/37/1070
Placing the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial in context
Distiller, L. A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872289
Génétique, acides gras oméga-3 et facteurs de risque des maladies cardiovasculaires
Bouchard‐Mercier, A. (2015) · Corpus Université Laval (Université Laval)
ω-3 Fatty Acids for Cardiovascular Disease Prevention in Patients with Diabetes
Brett, A. S. (2012) · Journal watch · doi:10.1056/jw201206120000002
Zou, L. (2014) · TSpace (University of Toronto)
Dietary regimens for persons with type 2 diabetes: Recommendations, issues and potential solutions
Stanojevic, V., & Jevtić, M. (2017) · Medicinski pregled · doi:10.2298/mpns1706177s
Yates, T. E., Davies, M. J., Jung, H., Bosch, J., Spinas, G. A., Sreenan, S., Commerford, P., & Gerstein, H. C. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.07.035
Serhiyenko, V. A., & Serhiyenko, O. (2017) · Lviv clinical bulletin · doi:10.25040/lkv2017.023.032
Combined bioactive approach over atherosclerosis risk biomarkers
Scolaro, B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2017.tde-07122017-163754
The effects of omega-3 supplementation on whole body and skeletal muscle energy metabolism in humans
Jannas-Vela, S. (2017) · The Atrium (University of Guelph)
Vitamins and Dietary Supplements for the Older Adult: What Works and Why?
Saad, M., Fausto, N., & Maisch, N. M. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000669
Lipids and Lipoprotein Mediators of Endothelial Function and Dysfunction
Oliveira, H. C. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812348-5.00021-0
Reactive Carbonyl Compounds: Their Control and Consequences in Foods
Freund, M. A. (2021) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · doi:10.7275/11933301
What should interventional cardiologists do for patients with prediabetes?
Danchin, N. (2018) · EuroIntervention · doi:10.4244/eijv14i9a173
LDL-Cholesterin: Die klar definierten Zielwerte ernst nehmen!
Parhofer, K. G. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-1120-x
Krychtiuk, K. A., & Speidl, W. S. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318820977
Cartolano, F. D. C. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2019.tde-10102018-080400
Ernährungstherapie des Typ-2-Diabetes
Hauner, H. (2013) · Humanmedizin kompakt · doi:10.1007/s40355-013-0017-2
Williston, M., Fontenot, M. S., Pope, J., & Erickson, D. (2019) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2019.06.078
Omega-3 Fatty Acids and the Cardiovascular System
Elagizi, A., & Lavie, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815238-6.00014-6
Acides gras oméga 3 à longue chaîne et risque cardiovasculaire, revue critique
Delarue, J. (2019) · Pratiques en nutrition · doi:10.1016/j.pranut.2019.05.004
2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment
Yamashita, S. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1685
МЕДИКАМЕНТОЗНАЯ ТЕРАПИЯ В ЛЕЧЕНИИ И ПРОФИЛАКТИКЕ ЖЕЛУДОЧКОВЫХ АРИТМИЙ И ВНЕЗАПНОЙ СЕРДЕЧНОЙ СМЕРТИ
Ватутин, Н. Т., Тарадин, Г. Г., & Реутова, Н. О. (2019) · Университетская клиника · doi:10.26435/uc.v0i4(33).328
Correction of dyslipidemia in patients with ischemic heart disease and diabetes mellitus type 2
Bentsa, T. М. (2016) · Medicine of Ukraine · doi:10.37987/1997-9894.2016.5-6(201-2).204728
Rist, K. (2020) · NORA - Norwegian Open Research Archives
Meyer, B. J. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-972-2
2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment
Yamashita, S. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.96a
Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease
Maniar, S., & Bittner, V. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_54-1
Serhiyenko, V. A., Azhmi, S., Serhiyenko, L. M., & Serhiyenko, A. A. (2018) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2018.4.06
Bloomgarden, Z. T. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12865
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch12
Precision Medicine for Diabetes and Dyslipidemia
Alexander, E., Cristiano, E., & Miles, J. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_3
Role of natural fatty acids in prophylaxis and treatment of cardiovascular diseases
Niezgoda, J., Przerwa, F., Kukowka, A., Aleksandrzak, J., Kotrych, K., & Uzar, I. (2022) · Herba Polonica · doi:10.2478/hepo-2022-0017
Rabast, U. (2022) · Springer eBooks · doi:10.1007/978-3-662-65230-5_2
MODERN APPROACHES IN THE TREATMENT OF DYSLIPIDEMIA AND FUTURE PERSPECTIVES
TABUKASHVILI, R., KAPETIVADZE, V., KAPETIVADZE, I., Silagadze, T. K., Kuparadze, M., MAGLAPERIDZE, Z., & LAZASHVILI, T. (2023) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2023.02.10
Ganda, O. P., Busch, R. S., Nelson, J. R., & Philip, S. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_25
Features of the metabolism of polyunsaturated fatty acids in type 2 diabetes mellitus
KhKh, S., Исмаиловна, А. Р., Плотникова, О. А., Пилипенко, В. В., & EIu, S. (2023) · Voprosy Pitaniya · doi:10.33029/0042-8833-2023-92-3-15-24
Krishnamurthy, H. A., Bhangari, V. S., & Sandesh, L. (2023) · Journal of Medical and Scientific Research · doi:10.17727/jmsr.2023/11-39
Langkettige Omega-3-Fettsäuren EPA und DHA
Bayer, W., Mahler, A., Schmidt, K., & Willmann, M. (2023) · Ernährung & Medizin · doi:10.1055/a-2151-9012
ICOSAPENT ETHYL AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES (NARRATIVE REVIEW)
Serhiyenko, V. A., Serhiyenko, L., Cherkas, A., & Serhiyenko, A. A. (2023) · Proceedings of the Shevchenko Scientific Society Medical Sciences · doi:10.25040/ntsh2023.02.06
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
